Table 5. Five-year BCSS assessed by AUC in multiple staging systems in training, internal validation, and external validation group.
| BCSS | Training group | Internal validation group | External validation group | |||||||||||||
| AUC (95% CI) | Pa | Pb | Pc | AUC (95% CI) | Pa | Pb | Pc | AUC (95% CI) | Pa | Pb | Pc | |||||
| BCSS, breast cancer-specific survival; AUC, area under the curve; CS, clinical stage; PS, pathologic stage; 95% CI, 95% confidence interval; a, Contrast estimate with PS as reference; b, Contrast estimate with CPS+EG as reference; c, Contrast estimate with Neo-Bioscore as reference. | ||||||||||||||||
| CS | 0.701 (0.615−0.788) |
0.650 (0.532−0.769) |
0.583 (0.429−0.737) |
|||||||||||||
| PS | 0.725 (0.647−0.803) |
0.700 (0.578−0.817) |
0.662 (0.517−0.818) |
|||||||||||||
| CPS+EG | 0.715 (0.641−0.789) |
0.999 | 0.637 (0.516−0.758) |
0.003 | 0.636 (0.478−0.795) |
0.788 | ||||||||||
| Neo-Bioscore | 0.716 (0.639−0.794) |
0.999 | 0.999 | 0.730 (0.606−0.801) |
0.630 | 0.031 | 0.678 (0.523−0.833) |
0.896 | 0.010 | |||||||
| CPS+EGHlow | 0.815 (0.742−0.888) |
0.038 | 0.007 | 0.004 | 0.762 (0.640−0.884) |
0.022 | <0.001 | 0.038 | 0.712 (0.551−0.872) |
0.040 | 0.009 | 0.049 | ||||